85%Confidence
0Views
FDASource
2026-03-23Date
Summary
Rising Pharma's Temozolomide recall due to stability testing failures indicates potential quality issues with oncology generic manufacturing. This could impact cancer treatment supply and increase regulatory scrutiny on Rising's manufacturing partners in Taiwan.
Actionable: Review oncology drug inventory for Rising Pharma products and assess potential alternative suppliers for Temozolomide.
AI Confidence: 85%
Data Points
firmRising Pharma Holding, Inc.
classificationClass II
statusOngoing
distributionNationwide within the U.S
productProduct label: Temozolomide Capsules, 5mg, packaged in 5-capsule bottles, Rx only, Manufactured for: Rising Pharmaceuticals, Inc., Allendale, NJ 07401
Get Signals Instantly
Premium subscribers receive every signal via Telegram the moment it fires — hours before it appears here.
Subscribe Now